메뉴 건너뛰기




Volumn 2015, Issue 8, 2015, Pages

Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G; PSEUDOMONAS VACCINE;

EID: 84991267415     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001399.pub4     Document Type: Review
Times cited : (18)

References (34)
  • 1
    • 3543002754 scopus 로고    scopus 로고
    • Relevant issues in bacterial vaccine development for patients with cystic fibrosis [abstract]
    • Döring G. Relevant issues in bacterial vaccine development for patients with cystic fibrosis [abstract]. Pedaitric Pulmonology 2003;Suppl 25:128-9.
    • (2003) Pedaitric Pulmonology , pp. 128-129
    • Döring, G.1
  • 2
    • 0031063067 scopus 로고    scopus 로고
    • A multicenter trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis
    • Döring G, Dorner F. A multicenter trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis. Behring Institute Mitteilungen 1997;98:338-44.
    • (1997) Behring Institute Mitteilungen , vol.98 , pp. 338-344
    • Döring, G.1    Dorner, F.2
  • 3
    • 34547432470 scopus 로고    scopus 로고
    • A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients
    • Döring G, Meisner C, Stern M, for the Flagella Vaccine Trial Study Group. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proceedings of the National Academy of Science USA 2007;104:11020-5.
    • (2007) Proceedings of the National Academy of Science USA , vol.104 , pp. 11020-11025
    • Döring, G.1    Meisner, C.2    Stern, M.3
  • 4
    • 85041728765 scopus 로고    scopus 로고
    • Clinical trial protocol, No. KV 9909. Double-blind, randomised, placebo-controlled, multi-centre trial to determine the efficacy of Aerugen Berna Vaccine to prevent respiratory tract infections with P. aeruginosa in non-colonised patients with cystic fibrosis
    • 2000 (May)
    • Clinical trial protocol, No. KV 9909. Double-blind, randomised, placebo-controlled, multi-centre trial to determine the efficacy of Aerugen Berna Vaccine to prevent respiratory tract infections with P. aeruginosa in non-colonised patients with cystic fibrosis. Medical Department, Swiss Serum and Vaccine Institute, Bern 2000 (May).
    • Medical Department, Swiss Serum and Vaccine Institute, Bern
  • 5
    • 85041742897 scopus 로고    scopus 로고
    • Crucell announces suspension of Aerugen(R) clinical development
    • (accessed 19 Dec)
    • Press release. Crucell announces suspension of Aerugen(R) clinical development. http://cws.huginonline.com/C/132631/PR/200607/1064252_5.html (accessed 19 Dec 2007).
    • (2007)
  • 10
    • 0021711007 scopus 로고
    • Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis - three year results
    • Langford DT, Hiller J. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis - three year results. Archives of Disease in Childhood 1984;59(12):1131-4.
    • (1984) Archives of Disease in Childhood , vol.59 , Issue.12 , pp. 1131-1134
    • Langford, D.T.1    Hiller, J.2
  • 12
    • 85041717924 scopus 로고
    • Early trials of Pseudomonas vaccine in Cystic Fibrosis [abstract]
    • 1970 April 29; Atlantic City
    • Gibbs GE. Early trials of Pseudomonas vaccine in Cystic Fibrosis [abstract]. Proceedings of the 11th Annual Meeting Cystic Fibrosis Club; 1970 April 29; Atlantic City. 1970:14.
    • (1970) Proceedingsof the 11th Annual Meeting Cystic Fibrosis Club , pp. 14
    • Gibbs, G.E.1
  • 13
    • 0031063093 scopus 로고    scopus 로고
    • Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-Polysaccharide-Toxin A conjugate vaccine
    • Cryz SJ, Lang A, Rudeberg A, Wedgewood J, Que JU, Furer E, et al. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-Polysaccharide-Toxin A conjugate vaccine. Behring Institute Mitteilungen 1997;98:345-9.
    • (1997) Behring Institute Mitteilungen , vol.98 , pp. 345-349
    • Cryz, S.J.1    Lang, A.2    Rudeberg, A.3    Wedgewood, J.4    Que, J.U.5    Furer, E.6
  • 14
    • 55049092231 scopus 로고    scopus 로고
    • Longterm protection against Pseudomonas aeruginosa (PA) infections in patients with cystic fibrosis (CF): results of a 9-year vaccine study [abstract]
    • Lang AB, Rudeberg A, Que JU, Wedgewood J, Furer E, Schaad UB, et al. Longterm protection against Pseudomonas aeruginosa (PA) infections in patients with cystic fibrosis (CF): results of a 9-year vaccine study [abstract]. Netherlands Journal of Medicine 1999;54(Suppl):s49.
    • (1999) Netherlands Journal of Medicine , vol.54 , pp. s49
    • Lang, A.B.1    Rudeberg, A.2    Que, J.U.3    Wedgewood, J.4    Furer, E.5    Schaad, U.B.6
  • 16
    • 3042638668 scopus 로고    scopus 로고
    • Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection
    • Lang AB, Ruedeberg A, Schöni MH, Que JU, Furer E, Schaad UB. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatric Infectious Disease Journal 2004;23(6):504-10.
    • (2004) Pediatric Infectious Disease Journal , vol.23 , Issue.6 , pp. 504-510
    • Lang, A.B.1    Ruedeberg, A.2    Schöni, M.H.3    Que, J.U.4    Furer, E.5    Schaad, U.B.6
  • 17
    • 0025950064 scopus 로고
    • Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis
    • Schaad UB, Lang AB, Wedgewood J, Rudeberg A, Que JU, Furer E, et al. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet 1991;338(8777):1236-7.
    • (1991) Lancet , vol.338 , Issue.8777 , pp. 1236-1237
    • Schaad, U.B.1    Lang, A.B.2    Wedgewood, J.3    Rudeberg, A.4    Que, J.U.5    Furer, E.6
  • 18
    • 0002236565 scopus 로고
    • Immunology of cystic fibrosis
    • London: Chapman & Hall Medical
    • Döring G, Bellon G, Knight R. Immunology of cystic fibrosis. Cystic Fibrosis. London: Chapman & Hall Medical, 1995.
    • (1995) Cystic Fibrosis
    • Döring, G.1    Bellon, G.2    Knight, R.3
  • 19
    • 0033773012 scopus 로고    scopus 로고
    • Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus
    • Döring G, Conway SP, Heijerman HGM, Hodson M, Høiby N, Smyth A, Touw DJ for the Consensus Committee. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. European Respiratory Journal 2000;16(4):749-67.
    • (2000) European Respiratory Journal , vol.16 , Issue.4 , pp. 749-767
    • Döring, G.1    Conway, S.P.2    Heijerman, H.G.M.3    Hodson, M.4    Høiby, N.5    Smyth, A.6
  • 20
    • 3343023861 scopus 로고    scopus 로고
    • Early intervention and prevention of lung disease in cystic fibrosis: a European consensus
    • Döring G, Høiby N for the Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. Journal of Cystic Fibrosis 2004;3(2):67-91.
    • (2004) Journal of Cystic Fibrosis , vol.3 , Issue.2 , pp. 67-91
    • Döring, G.1
  • 23
    • 0002414405 scopus 로고
    • Microbiology of cystic fibrosis
    • In: Hodson ME, Geddes DM editor(s). London: Chapman & Hall Medical
    • Høiby N. Microbiology of cystic fibrosis. In: Hodson ME, Geddes DM editor(s). Cystic Fibrosis. London: Chapman & Hall Medical, 1995.
    • (1995) Cystic Fibrosis
    • Høiby, N.1
  • 24
    • 0033653318 scopus 로고    scopus 로고
    • Prospective for the prevention and control of Pseudomonas infection in children with cystic fibrosis
    • Høiby N. Prospective for the prevention and control of Pseudomonas infection in children with cystic fibrosis. Pediatric Drugs 2000;2(6):451-63.
    • (2000) Pediatric Drugs , vol.2 , Issue.6 , pp. 451-463
    • Høiby, N.1
  • 26
    • 0002382384 scopus 로고
    • The epidemiology of cystic fibrosis
    • In: Hodson ME, Geddes D editor(s). London: Chapman and Hall
    • Lewis PA. The epidemiology of cystic fibrosis. In: Hodson ME, Geddes D editor(s). Cystic Fibrosis. London: Chapman and Hall, 1995:1-13.
    • (1995) Cystic Fibrosis , pp. 1-13
    • Lewis, P.A.1
  • 28
    • 0029849044 scopus 로고    scopus 로고
    • Reduced IL-10 secretion by CD4+T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR)
    • Moss RB, Bocian RC, Hsu YP, Dong YJ, Kemna M, Wei T, et al. Reduced IL-10 secretion by CD4+T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clinical and Experimental Immunology 1996;106(2):374-88.
    • (1996) Clinical and Experimental Immunology , vol.106 , Issue.2 , pp. 374-388
    • Moss, R.B.1    Bocian, R.C.2    Hsu, Y.P.3    Dong, Y.J.4    Kemna, M.5    Wei, T.6
  • 29
    • 85047692188 scopus 로고
    • Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
    • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
    • (1995) JAMA , vol.273 , Issue.5 , pp. 408-412
    • Schulz, K.F.1    Chalmers, I.2    Hayes, R.J.3    Altman, D.G.4
  • 30
    • 0000963297 scopus 로고
    • The Pathology of Cystic Fibrosis
    • In: Hodson ME, Geddes DM editor(s). London: Chapman & Hall Medical
    • Sheppard MN. The Pathology of Cystic Fibrosis. In: Hodson ME, Geddes DM editor(s). Cystic Fibrosis. London: Chapman & Hall Medical, 1995.
    • (1995) Cystic Fibrosis
    • Sheppard, M.N.1
  • 31
    • 0021270246 scopus 로고
    • Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study
    • Wheeler WB, Williams RN, Matthews WJ, Colten HR. Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study. Journal of Pediatrics 1984;104(5):695-9.
    • (1984) Journal of Pediatrics , vol.104 , Issue.5 , pp. 695-699
    • Wheeler, W.B.1    Williams, R.N.2    Matthews, W.J.3    Colten, H.R.4
  • 32
    • 55049131107 scopus 로고    scopus 로고
    • Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis
    • Johansen HK, Gøtzsche PC, Keogan MT. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD001399.pub2]
    • (2008) Cochrane Database of Systematic Reviews , Issue.4
    • Johansen, H.K.1    Gøtzsche, P.C.2    Keogan, M.T.3
  • 33
    • 84891705714 scopus 로고    scopus 로고
    • Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis
    • Johansen HK, Gøtzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD001399.pub3]
    • (2013) Cochrane Database of Systematic Reviews , Issue.6
    • Johansen, H.K.1    Gøtzsche, P.C.2
  • 34
    • 84991267415 scopus 로고    scopus 로고
    • Vaccines for preventing infection with Pseudomonas aeruginosa in people with cystic fibrosis
    • Keogan MT, Johansen HK. Vaccines for preventing infection with Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews 1999, Issue 1. [DOI: 10.1002/14651858.CD001399]
    • (1999) Cochrane Database of Systematic Reviews , Issue.1
    • Keogan, M.T.1    Johansen, H.K.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.